American Association for Cancer Research
Browse
00085472can171636-sup-184217_3_supp_4343419_gy4ljj_rtf_zip.zip (1.12 MB)

Figure S4 and Legend from MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer

Download (1.12 MB)
software
posted on 2023-03-31, 01:06 authored by Takahiro Maeda, Masayuki Hiraki, Caining Jin, Hasan Rajabi, Ashujit Tagde, Maroof Alam, Audrey Bouillez, Xiufeng Hu, Yozo Suzuki, Masaaki Miyo, Tsuyoshi Hata, Kunihiko Hinohara, Donald Kufe

This file contains the results of studies with Eo771 cells stably expressing MUC1-C (S4A and S4B), demonstrating that treatment of these cells with JQ1 (S4C), BAY-11-7085 (S4D) or GO-203/NPs (S4E) decreases PD-L1 expression.

Funding

National Cancer Institute of the National Institutes of Health

History

ARTICLE ABSTRACT

The immune checkpoint ligand PD-L1 and the transmembrane mucin MUC1 are upregulated in triple-negative breast cancer (TNBC), where they contribute to its aggressive pathogenesis. Here, we report that genetic or pharmacological targeting of the oncogenic MUC1 subunit MUC1-C is sufficient to suppress PD-L1 expression in TNBC cells. Mechanistic investigations showed that MUC1-C acted to elevate PD-L1 transcription by recruitment of MYC and NF-κB p65 to the PD-L1 promoter. In an immunocompetent model of TNBC in which Eo771/MUC1-C cells were engrafted into MUC1 transgenic mice, we showed that targeting MUC1-C associated with PD-L1 suppression, increases in tumor-infiltrating CD8+ T cells and tumor cell killing. MUC1 expression in TNBCs also correlated inversely with CD8, CD69, and GZMB, and downregulation of these markers associated with decreased survival. Taken together, our findings show how MUC1 contributes to immune escape in TNBC, and they offer a rationale to target MUC1-C as a novel immunotherapeutic approach for TNBC treatment.Significance: These findings show how upregulation of the transmembrane mucin MUC1 contributes to immune escape in an aggressive form of breast cancer, with potential implications for a novel immunotherapeutic approach. Cancer Res; 78(1); 205–15. ©2017 AACR.